Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

PURPOSE: To evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of trebananib (AMG 386)—a first-in-class angiopoietin-1/2 antagonist peptide-Fc fusion protein—in Japanese patients, we conducted a phase 1, dose escalation study. METHODS: Eligible patients were men or women, ag...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Doi, Toshihiko, Ohtsu, Atsushi, Fuse, Nozomu, Yoshino, Takayuki, Tahara, Makoto, Shibayama, Kazuhiro, Takubo, Takatoshi, Weinreich, David M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2012
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3535401/
https://ncbi.nlm.nih.gov/pubmed/23124648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-2000-1
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky